Core Viewpoint - Morgan Stanley analyst Terence Flynn has raised the price target for Bristol Myers (BMY) to $40 from $37 while maintaining an Underweight rating on the shares [1] Revenue and EPS Guidance - The 2026 revenue and EPS guidance for Bristol Myers came in above consensus expectations [1] - This positive outlook was primarily driven by a higher than expected guidance for Eliquis [1]

We recently published 12 Stocks Jim Cramer Talked About.  Bristol Myers Squibb Company (NYSE:BMY) is one of the stocks that Jim Cramer talked about. Bristol Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. Its shares are up by 7.5% over the past year and by 15.4% year-to-date. Piper Sandler bumped its Bristol Myers Squibb Company (NYSE:BMY) share price target to $66 from $62 and kept an Overweight rating on the shares in late January. The pharma company’s drug p ...

It has been one year since I last covered Bristol-Myers Squibb ( BMY ), rating the stock a Hold . That article followed Q4 2024 earnings, when investors were spooked by declining 2025Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as i ...

Core Viewpoint - Morgan Stanley maintains an "Underweight" rating for Bristol-Myers Squibb, advising investors to hold the stock, which is priced around $61.46 [1][6] Company Strategy - Bristol-Myers Squibb's "focused execution" strategy in 2025 has positively influenced its outlook for 2026, emphasizing newer brands and late-stage pipeline catalysts while managing costs to counteract loss-of-exclusivity challenges [2] Financial Performance - In Q4 2025, Bristol-Myers Squibb reported a strong performance with a growth portfolio increase of 15% year-over-year, which nearly offset a $4 billion revenue decline from its legacy portfolio [3][6] - The total revenue for Q4 remained stable at approximately $12.5 billion, with a stock price increase of 3.44% to $61.57 [4][6] Market Data - The stock has fluctuated between $59.77 and $61.86, with a market capitalization of about $125.34 billion, and has seen a 52-week high of $63.33 and a low of $42.52 [4][5] - Trading volume stands at 5.4 million shares, indicating active market participation despite the "Underweight" rating [5]

CFO David Elkins reported fourth-quarter total revenue was flat year-over-year at approximately $12.5 billion. Growth portfolio revenue increased 15% to $7.4 billion and represented close to 60% of total revenue in the quarter. Elkins attributed the performance to growth from Reblozyl, Breyanzi, Camzyos, and the company’s immuno-oncology portfolio, supported by early launches of Cobenfy and Opdivo Subcutaneous.Chair and CEO Chris Boerner said the company closed 2025 with “strong fourth quarter performance,” ...

Core Viewpoint - Bristol Myers Squibb is focused on strengthening its position in the biopharmaceutical industry through a robust pipeline of late-stage assets and ongoing investments in innovation and shareholder returns [2][3][6]. Group 1: Company Performance and Pipeline - The company has a strong portfolio of early-stage assets that are showing growth potential, with significant opportunities for expansion [2][3]. - Bristol Myers Squibb is anticipating data readouts for six new products this year and has the potential for 11 phase three trials, indicating a rich pipeline for future growth [4][6]. - The company aims to introduce up to 10 new products and over 30 life cycle management opportunities by the end of the decade [4]. Group 2: Financial Outlook - Bristol Myers Squibb is financially strong, allowing for continued investment in business growth and capital returns to shareholders [3][6]. - The company is focused on delivering results from its late-stage assets, which represent the richest pipeline seen in recent years [5][6]. Group 3: Market and Competitive Landscape - The company is aware of competitive threats, particularly from China, which is heavily investing in biopharmaceuticals and aims to replicate the U.S. ecosystem [15][16]. - Bristol Myers Squibb emphasizes the importance of maintaining a strong innovation ecosystem in the U.S. to ensure patient access and affordability [13][16]. Group 4: Role of AI in Drug Development - AI is expected to transform the biopharmaceutical value chain, from basic research to commercialization, with goals to reduce drug development cycle times by 30% [17][18]. - The company utilizes AI models to predict the probability of success for research programs before they enter clinical development [18].

Bristol Myers Squibb (NYSE: BMY) stock was a rare bright light on a very dim Thursday for American equities. Encouraged by the company's good quarterly and annual earnings release, market players pushed the stock up by more than 3% on a day when the S&P 500 index slumped by more than 1%. Newer products carried the day Bristol Myers' fourth quarter of 2025 saw the veteran pharmaceutical company grow revenue by 1% year over year to $12.5 billion. Much of this was attributable to its so-called "growth portfo ...

Bristol Myers Squibb on Thursday delivered strong fourth quarter results — and better yet, issued a 2026 forecast that was above Wall Street expectations. Combine that with a single-digit price-to-earnings multiple and the simple fact that this isn't a software company, and you've got the makings of a stock that can keep the momentum going in the current market conditions. Revenue in the fourth quarter ended Dec. 31 ticked up 1% to $12.5 billion, ahead of the $12.28 billion expected, according to LSEG. Earn ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Thursday.The Dow traded down 0.86% to 49,073.13 while the NASDAQ dipped 1.03% to 22,669.07. The S&P 500 also fell, dropping, 0.91% to 6,820.34.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsReal estate shares gained by 0.1% on Thursday.In trading on Thursday, materials stocks fell by 2.2%.Top HeadlineBristol Myers Squibb & Co. (NYSE:BMY) ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Thursday.The Dow traded down 0.86% to 49,073.13 while the NASDAQ dipped 1.03% to 22,669.07. The S&P 500 also fell, dropping, 0.91% to 6,820.34.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsReal estate shares gained by 0.1% on Thursday.In trading on Thursday, materials stocks fell by 2.2%.Top HeadlineBristol Myers Squibb & Co. (NYSE:BMY) ...